The influence of electroporation on cytotoxicity of anticancer ruthenium(III) complex KP1339 in vitro and in vivo

Anticancer Research

Volumn 30, Issue 6, 2010, Pages 2055-2063

  Hudej, Rosana ^a   Turel, Iztok ^a   Kanduser, Masa ^a   Scancar, Janez ^c   Kranjc, Simona ^b   Sersa, Gregor ^b   Miklavcic, Damijan ^a   Jakupec, Michael A ^d   Keppler, Bernhard K ^d   Cemazar, Maja ^b  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b INSTITUTE OF ONCOLOGY   (Slovenia)

^c JO EF STEFAN INSTITUTE   (Slovenia)

^d UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anticancer ruthenium(III) compounds; Electrochemotherapy; Electroporation; KP1339; Mice; Sarcoma; Tumour models

Indexed keywords

KP 1339; RUTHENIUM COMPLEX; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL VIABILITY; CHO CELL; DOSE RESPONSE; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG TUMOR LEVEL; DRUG UPTAKE; ELECTROCHEMOTHERAPY; ELECTROPORATION; FEMALE; FIBROSARCOMA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPORATION; MICE; ORGANOMETALLIC COMPOUNDS; SARCOMA, EXPERIMENTAL;

EID: 77952525193     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Zimmermann U, Vienken J and Pilwat G: Development of drug carrier systems: electrical field induced effects in cell membranes. Bioelectrochem Bioenerg 7: 553-574, 1980.
2. Mir LM, Banoun H and Paoletti C: Introduction of definite amounts of nonpermeant molecule into living cells after electropermeabilization: direct access to the cytosol. Exp Cell Res 175: 15-25, 1988.
3. Sersa G: Electrochemotherapy. In: Electrochemotherapy, Electrogenetherapy, and Transdermal Drug Delivery. Electrically Mediated Delivery of Molecules to Cells. Jaroszeski MJ, Heller R and Gilbert R (eds.). New Jersey: Humana Press, pp. 119-136, 2000.
4. Heller R, Gilbert R and Jaroszeski MJ: Clinical trials for solid tumors using electrochemotherapy. In: Electrochemotherapy, Electrogenetherapy, and Transdermal Drug Delivery. Electrically Mediated Delivery of Molecules to Cells. Jaroszeski MJ, Heller R and Gilbert R (eds.). New Jersey: Humana Press, pp. 137-156, 2000.
5. Neumann E and Rosenheck K: Permeability changes induced by electric impulses in vesicular membranes. J Membr Biol 10: 279-290, 1972.
6. Neumann E, Sowers AE and Jordan CA: Electroporation and Electrofusion in Cell Biology. New York: Plenum Press, pp. 1-105, 1989.
7. Kinosita KJ and Tsong TY: Formation and resealing of pores of controlled sizes in human erythrocytes membrane. Nature 268: 438-441, 1977.
8. Weaver JC and Chizmadzhev YA: Theory of electroporation: A review. Bioelectrochem Bioenerg 41: 135-160, 1996.
9. Serpersu EH, Kinosita K Jr. and Tsong TY: Reversible and irreversible modification of erythrocyte-membrane permeability by electric field. Biochim Biophys Acta 812: 779-785, 1985.
10. Teissie J, Golzio M and Rols MP: Mechanisms of cell membrane electropermeabilization: A minireview of our present (lack of?) knowledge. Biochim Biophys Acta 1724: 270-280, 2005.
11. Pavlin M and Miklavčič D: Theoretical and experimental analysis of conductivity, ion diffusion and molecular transport during cell electroporation -Relation between short-lived and long-lived pores. Bioelectrochemistry 74: 38-46, 2008.
12. Orlowski S, Belehradek J Jr., Paoletti C and Mir LM: Transient electropermeabilization of cells in culture: increase of the cytotoxicity of anticancer drugs. Biochem Pharmacol 37: 4727-4733, 1988.
13. Okino M and Mohri H: Effects of high-voltage electrical impulse and an anticancer drug on in vivo growing tumors. Jpn J Cancer Res 78: 1319-1321, 1987.
14. Mir LM, Orlowski S, Belehradek J, Jr., and Paoletti C: Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. Eur J Cancer 27: 68-72, 1991.
15. Rudolf Z, Stabuc R, Cemazar M, Miklavcic D, Vodovnik L and Sersa G: Electrochemotherapy with bleomycin. The first clinical experience in malignant melanoma patients. Radiol Oncol 29: 229-235, 1995.
16. Sersa G, Cemazar M and Miklavcic D: Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum(II) in mice. Cancer Res 55: 3450-3455, 1995.
17. Sersa G, Stabuc B, Cemazar M, Jancar B, Miklavcic D and Rudolf Z: Electrochemotherapy with cisplatin - potentiation of local cisplatin antitumor effectiveness by application of electric pulses in cancer patients. Eur J Cancer 34: 1213-1218, 1998.
18. Zupanic A, Corovic S and Miklavcic D: Optimization of electrode position and electric pulse amplitude in electrochemotherapy. Radiol Oncol 42: 93-101, 2008.
19. Sersa G, Cemazar M, Miklavcic D and Chaplin DJ: Tumor blood flow modifying effect of electrochemotherapy with bleomycin. Anticancer Res 19: 4017-4022, 1999.
20. Sersa G, Krzic M, Sentjurc M, Ivanusa T, Beravs K, Kotnik V, Coer A, Swartz HM and Cemazar M: Reduced blood flow and oxygenation in SA-1 tumours after electrochemotherapy with cisplatin. Br J Cancer 87: 1047-1054, 2002.
21. Sersa G, Jarm T, Kotnik T, Coer A, Podkrajsek M, Sentjurc M, Miklavcic D, Kadivec M, Kranjc S, Secerov A and Cemazar M: Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma. Br J Cancer 98: 388-398, 2008.
22. Sersa G, Cemazar M and Miklavcic D: Tumor blood modifying effects of electrochemotherapy: a potential vascular-targeted mechanism. Radiol Oncol 37: 43-48, 2003.
23. Cemazar M, Parkins CS, Holder AL, Chaplin DJ, Tozer GM and Sersa G: Electroporation of human microvascular endothelial cells: evidence for an anti-vascular mechanism of electrochemotherapy. Br J Cancer 84: 565-570, 2001.
24. Mir LM, Tounekti O and Orlowski S: Bleomycin: Revival of an old drug: A review. Gen Pharmacol 27: 745-748, 1996. (Pubitemid 26295629)
25. Ang WH and Dyson PJ: Classical and non-classical ruthenium-based anticancer drugs: towards targeted chemotherapy. A review. Eur J Inorg Chem pp. 4003-4018, 2006.
26. Rademaker-Lakhai JM, van den Bongard D, Pluim D, Beijnen JH and Schellens JH: A phase I and pharmacological study with imidazolium trans-DMSO-imidazole- tetrachlororuthenate, a novel ruthenium anticancer agent. Cancer Res 10: 3717-3727, 2004.
27. Lentz F, Drescher A, Lindauer A, Henke M, Hilger RA, Hartinger CG, Scheulen ME, Dittrich C, Keppler BK and Jaehde U: Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study. Anticancer Drugs 20: 97-103, 2009.
28. Dyson PJ and Sava G: Metal-based antitumour drugs in the post genomic era. Dalton Trans, pp. 1929-1933, 2006.
29. Keppler BK, Henn M, Juhl UM, Berger MR, Niebl R and Wagner FE: New ruthenium complexes for the treatment of cancer. In: Progress in Clinical Biochemistry and Medicine 10. Clarke MJ (ed.). Berlin: Springer, pp. 41-69, 1989.
30. Kapitza S, Pongratz M, Jakupec MA, Heffeter P, Berger W, Lackinger L, Keppler BK and Marian B: Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells. J Cancer Res Clin Oncol 131: 101-110, 2005.
31. Berger MR, Garzon FT, Keppler BK and Schmàhl D: Efficacy of new ruthenium complexes against chemically induced autochthonous colorectal carcinoma in rats. Anticancer Res 9: 761-766, 1989.
32. Depenbrock H, Schmelcher S, Peter R, Keppler BK, Weirich G, Block T, Rastetter J and Hanauske AR: Preclinical activity of trans-indazolium [tetrachlorobisindazoleruthenate(III)] (NSC 666158; IndCR; KP1019) against tumour colony-forming units and haematopoietic progenitor cells. Eur J Cancer 33: 2404-2410, 1997.
33. Pieper T, Peti W and Keppler BK: Solvolysis of the tumor-inhibiting Ru(III)-complex trans-tetrachlorobis(indazole) ruthenate(III). Met Based Drugs 7: 225-232, 2000.
34. Bicek A, Turel I, Kanduser M and Miklavcic D: Combined therapy of the antimetastatic compound NAMI-A and electroporation on B16F1 tumour cells in vitro. Bioelectrochemistry 71: 113-117, 2007.
35. Cemazar M, Miklavcic D and Sersa G: Intrinsic sensitivity of tumor cells to bleomycin as an indicator of tumor response to electrochemotherapy. Jpn J Cancer Res 89: 328-333, 1998.
36. Poddevin B, Orlowski S, Belehradek J Jr. and Mir LM: Very high cytotoxicity of bleomycin introduced into the cytosol of cells in culture. Biochem Pharmacol 42: 67-75, 1991.
37. Pron G, Mahrour N, Orlowski S, Tounekti O, Poddevin B, Belehradek J, Jr., and Mir LM: Internalisation of the bleomycin molecules responsible for bleomycin toxicity: a receptor-mediated endocytosis mechanism. Biochem Pharmacol 57: 45-56, 1999.
38. Sersa G, Miklavcic D, Cemazar M, Rudolf Z, Pucihar G and Snoj M: Electrochemotherapy in treatment of tumours. EJSO 34: 232-240, 2008.
39. Bergamo A and Sava G: Ruthenium complexes can target determinants of tumour malignancy. Dalton Trans, pp. 1267-1272, 2007.
40. Kratz F, Keppler BK, Hartmann M, Messori L and Berger MR: Comparison of the antiproliferative activity of two antitumour ruthenium(III) complexes with their apotransferrin and transferring-bound forms in a human colon cancer cell line. Met Based Drugs 3: 15-23, 1996.
41. Cemazar M, Miklavcic D, Scancar J, Dolzan V, Golouh R and Sersa G: Increased platinum accumulation in SA-1 tumour cells after in vivo electrochemotherapy with cisplatin. Br J Cancer 79: 1386-1391, 1999.
42. 2] and serum proteins. J Inorg Biochem 98: 1135-1142, 2004.
43. Keppler BK, Lipponer KG, Stenzel B and Kratz F: New tumor-inhibiting ruthenium complexes. In: Metal Complexes in Cancer Chemotherapy. Keppler BK (ed.). New York: Wiley, John & Sons, Incorp., pp. 187-220, 1993.
44. Gately DP and Howell SB: Cellular accumulation of the anticancer agent cisplatin: A review. Br J Cancer 67: 1171-1176, 1993.
45. Ivanov AI, Christodoulou J, Parkinson JA, Barnham KJ, Tucker A, Woodrow J and Sadler PJ: Cisplatin binding sites on human albumin. J Biol Chem 273: 14721-14730, 1998.
46. Morbidelli L, Donnini S, Filippi S, Messori L, Piccioli F, Orioli P, Sava G and Ziche M: Antiangiogenic properties of elected ruthenium(III) complexes that are nitric oxide scavengers. Br J Cancer 88: 1484-1491, 2003.